+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank

Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank

Clinical Therapeutics 31(8): 1871-80; Discussion 1858

The aim of this study was to identify factors associated with the initiation of biologic agents for the treatment of rheumatoid arthritis (RA) in a large US observational cohort. Semiannual patient-reported data in the ARAMIS (Arthritis, Rheumatism and Aging Medical Information System) data bank from January 1998 to January 2006 were analyzed retrospectively using pooled logistic regression (with adjustment for center-level and temporal effects) to identify patient-, disease-, and treatment-related characteristics associated with the initiation of biologics for the treatment of RA. The analysis included 1545 patients from 7 US centers. By 2006, 41.4% of 679 patients remaining in the sample had received biologics. Initiation of biologics was significantly associated with greater disability in the previous 6-month period (per 1-unit increase in Health Assessment Questionnaire score: odds ratio [OR] = 1.45; 95% CI, 1.22-1.72; P < 0.01) and treatment in the previous period with steroids (OR = 2.24; 95% CI, 1.76-2.85; P < 0.01) or nonbiologic disease-modifying antirheumatic drugs (OR = 2.43; 95% CI, 1.71-3.46; P < 0.01). Two sociodemographic factors were significant predictors of decreased use of biologics: older age (per 10 years: OR = 0.74; 95% CI, 0.660.82; P < 0.01) and lower annual income (per $10,000 reduction: OR = 0.95; 95% CI, 0.91-1.00; P = 0.04). There were no significant differences with respect to sex, race, employment status, comorbidity, previous NSAID use, or treatment center. Disease- and treatment-related factors were significant predictors of the initiation of biologics for RA. Independent of these factors, however, biologics were less often used in patients who were older and those with lower incomes. Use of biologics increased steadily over the period studied.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054895474

Download citation: RISBibTeXText

PMID: 19808146

DOI: 10.1016/j.clinthera.2009.08.020

Related references

Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. Current Medical Research and Opinion 33(1): 101-107, 2016

A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States. Rheumatology and Therapy 5(1): 255-270, 2017

Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bulletin of the Nyu Hospital for Joint Diseases 66(2): 77-85, 2008

Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-Naive Rheumatoid Arthritis Patients. Arthritis Care and Research 70(7): 997-1004, 2018

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis and Rheumatism 56(9): 2886-2895, 2007

Biologic Treatment of Rheumatoid Arthritis and the Risk of Malignancy: Analyses From a Large US Observational Study. Yearbook of Medicine 2009: 21-22, 2009

Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. The Journal of Rheumatology 44(2): 262-263, 2017

Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry. Joint, Bone, Spine 80(2): 160-164, 2013

Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry. Arthritis Care and Research 68(7): 914-921, 2017

AB0468Channeling of Biologic Agents: Comparing Baseline Characteristics of Biologic Nave Rheumatoid Arthritis Patients Initiating Abatacept, as Compared to Other Biologic Agents and Small Molecule Agents. Annals of the Rheumatic Diseases 74(Suppl 2): 1052.2-1053, 2015

Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. Journal of Rheumatology 37(12): 2566-2572, 2011

Fri0001Good Response after Three Months of Treatment with Biologic Agents May Predict Long-Term Efficacy of Biologic Treatment in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases 73(Suppl 2): 381.1-381, 2014

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis and Rheumatism 63(2): 337-345, 2011

Predictors for progression of two different types of cervical lesions in rheumatoid arthritis treated with biologic agents. Journal of Orthopaedic Science 2018, 2018

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. Journal of Rheumatology 39(6): 1198-1206, 2012